Sequencing therapy in advanced prostate cancer: Focus on sipuleucel-T

Expert Review of Anticancer Therapy

Volumn 14, Issue 1, 2014, Pages 51-61

  Quinn, David I ^a   Vaishampayan, Ulka ^b   Higano, Celestia S ^c   Lin, Daniel W ^c   Shore, Neal D ^d   Beer, Tomasz M ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Carolina Urologic Research Center/Atlantic Urology Clinics   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

abiraterone; drug therapy; early detection of cancer; enzalutamide; immunotherapy; ipilimumab; neoplasm metastasis; prostatic neoplasms; radium 223; sipuleucel T

Indexed keywords

ABIRATERONE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; ANTINEOPLASTIC AGENT; APC 8015F; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; ESTROGEN; IPILIMUMAB; KETOCONAZOLE; NILUTAMIDE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; LOW DRUG DOSE; MALE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TIME FACTORS; TISSUE EXTRACTS;

EID: 84893037371     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.848065     Document Type: Review

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 63(1), 11-30 (2013
2. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer. Curr. Opin. Urol. 15(3), 181-186 (2005
3. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138-148 (2013
4. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10(8), 580-593 (2010
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
6. Higano CS, Small EJ, Schellhammer P et al. Sipuleucel-T. Nat. Rev. Drug Discov. 9(7), 513-514 (2010
7. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006
8. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009
9. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 81(6), 1297-1302 (2013
10. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
11. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-Targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010
12. Gulley JL, Drake CG. Immunotherapy for prostate cancer: Recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17(12), 3884-3891 (2011
13. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression. Oncologist 15(9), 969-975 (2010
14. Sheikh N, Petrylak D, Poehlein C et al. Sipuleucel-T: Adaptive immune response and product characterization from the phase III IMPACT trial. Abstract 104. presented at: The Association for Cancer Immunotherapy (CIMT) 9th Annual Meeting. Mainz, DE, 25-27 May 2011
15. Beer TM, Bernstein GT, Corman JM et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 17, 4558-4567 (2011
16. Sheikh NA, Small EJ, Quinn DI et al. Sipuleucel-T product characterization across different disease states of prostate cancer. J. Clin. Oncol. 30(Suppl.), Abstract 21 (2012
17. Kanda N, Watanabe S. Ketoconazole suppresses interleukin-4 plus anti-CD40-induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis. J. Invest. Dermatol. 119(3), 590-599 (2002
18. Beetens JR, Loots W, Somers Y, Coene MC, De Clerck F. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem. Pharmacol. 35(6), 883-891 (1986
19. Baroni A, Ruocco V, De Paolis P, Cicatiello L, Esumi H, Tufano MA. Ketoconazole inhibits lipopolysaccharide-induced activation of the nitric oxide synthase gene in the murine macrophage cell line J774. Arch. Dermatol. Res. 291(1), 54-58 (1999
20. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: Implications for combination therapy of prostate cancer. Front. Biosci. 12, 4957-4971 (2007
21. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 355(9214), 1491-1498 (2000
22. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J. Clin. Oncol. 22(6), 1025-1033 (2004
23. Chen Y, Clegg NJ, Scher HI. Anti-Androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol. 10(10), 981-991 (2009
24. Attard G, Reid AHM, de Bono JS. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J. Clin. Oncol. 28(29), e560-e561 (2010
25. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28(9), 1481-1488 (2010
26. Attard G, Reid AHM, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27(23), 3742-3748 (2009
27. Attard G, Reid AHM, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26(28), 4563-4571 (2008
28. Logothetis C, de Bono JS, Molina A et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. J. Clin. Oncol. 29(Suppl.), Abstract 4520 (2011
29. Parker C, Nilsson S, Heinrich D et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J. Clin. Oncol. 30(Suppl.), Abstract LBA4512 (2012
30. Hersey P, Zhang XD. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunol. Immunother. 58(11), 1749-1759 (2009
31. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012
32. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009
33. Agus DB, Stadler WM, Shevrin DH et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. J. Clin. Oncol. 29(Suppl.), Abstract 4531 (2011
34. Saad F, Akaza H, Eisenberger MA et al. A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-nai?ve metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 29(Suppl.), Abstract TPS184 (2011
35. Jennbacken K, Welen K, Olsson A et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate 72(8), 913-924 (2012
36. Pili R, Haggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J. Clin. Oncol. 29(30), 4022-4028 (2011
37. Slovin SF, Beer TM, Higano CS et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 27(Suppl.), Abstract 5138 (2009
38. Sheikh NA, Petrylak D, Kantoff PW et al. Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 62(1), 137-147 (2013
39. Tombal B, Lecouvet F. Modern detection of prostate cancer's bone metastasis: Is the bone scan era over? Adv. Urol. 2012, 893193 (2012
40. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004
41. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011
42. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376(9747), 1147-1154 (2010